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Recent studies have suggested that brain tumors arise from neural stem cells and are maintained by stem-
like tumor-initiating cells (TICs). In this issue of Cancer Cell, Persson et al. report that oligodendrogliomas,
unlike malignant astrocytomas, originate from—and are propagated by—cells that resemble oligodendro-
cyte progenitors.Before the advent of Google and Face-
book, if you wanted to know something
about a stranger, you’d ask where they
were born, who their parents were, and
what they did for a living. Just as you
can tell a lot about a person’s character
by knowing where they come from, you
can learn a lot about a cancer by under-
standing its origins. Identifying the cell
from which a tumor arises allows investi-
gators to define key similarities and differ-
ences between tumor cells and their
normal counterparts that may facilitate
tumor cell targeting. In addition, cells
resembling the cell of origin may persist
in tumors and may be essential for long-
term tumor growth. If so, identifying the
cell of origin, and understanding its
vulnerabilities, may be critical for devel-
oping more effective therapies.
Gliomas—including astrocytomas and
oligodendrogliomas—are the most com-
mon primary brain tumors in adults.
Despite extensive research into the
molecular basis of gliomas, current thera-
pies remain ineffective, and themajority of
patients die from their disease. More
effective therapeutic strategies are likely
to come from a deeper understanding of
glioma origins (Figure 1).
The fact that gliomas histologically
resemble glial cells initially suggested
that they arose from glial progenitors:
astrocytomas from astrocytic progenitor
cells and oligodendrogliomas from oligo-
dendrocyte progenitor cells (OPCs).
However, recent studies have provided
compelling evidence that high-grade
astrocytomas arise from multipotent
neural stem cells (NSCs). Conditionally
deleting the tumor suppressors NF1,
p53, and PTEN in NSCs—by activating
a Nestin-Cre transgene or by injecting546 Cancer Cell 18, December 14, 2010 ª20Cre viruses into the subventricular zone
(SVZ)—induces malignant astrocytomas,
whereas targeting the same mutations to
the cortex or striatum fails to induce
tumors (Alcantara Llaguno et al., 2009).
Likewise, lentiviral transduction of onco-
genic Ras and Akt into the SVZ or hippo-
campus causes astrocytomas, whereas
nonneurogenic brain regions are resistant
to transformation (Marumoto et al., 2009).
These studies suggest that malignant
astrocytomas originate from stem cells.
In contrast, the origins of oligodendro-
glioma remain controversial. The epi-
dermal growth factor (EGF) and platelet-
derived growth factor (PDGF) pathways
have both been implicated in the etiology
of oligodendroglioma, and retroviruses
encoding these ligands induce prolifera-
tion of stem cells in the SVZ and OPCs
in the white matter (WM) (Assanah et al.,
2006; Dai et al., 2001; Ivkovic et al.,
2008). But the fact that the driving force
for tumorigenesis in these studies is
a secreted growth factor (which affects
not only virally infected cells but also their
neighbors) makes definitive identification
of the cell of origin difficult.
To investigate the origin of oligodendro-
gliomas driven by cell-autonomous sig-
nals, Persson et al. (2010) used a model
in which expression of an oncogenic EGF
receptor (v-erbB) is driven by the human
S100b promoter. S100b is expressed in
OPCs committed to differentiate along
theoligodendrocyte lineage.S100b-verbB
transgenic mice develop low-grade oligo-
dendrogliomas; when they are crossed to
mice carrying mutations in p53, tumors
occur with shorter latency and become
more malignant. Persson et al. (2010)
report that in thesemice, the earliest signs
of increasedproliferationare seen inNG2+10 Elsevier Inc.OPCs in the WM and not in NSCs in the
SVZ.Moreover, in contrast to astrocytoma
cells, which frequently express NSC
markers and exhibit multilineage differen-
tiation, S100b-verbB tumor cells express
markers of OPCs and differentiate almost
exclusively into oligodendrocytes. Impor-
tantly, similar properties—localization
near theWM, expression of OPCmarkers,
and limited differentiation potential—are
associated with human oligodendroglio-
mas. These findings suggest that oligo-
dendrogliomas arise from OPCs rather
than stem cells.
In addition to originating fromstemcells,
astrocytomas have been reported to
contain stem-like tumor-initiating cells
(TICs) that are critical for tumor propaga-
tion. Marked by expression of CD133
(Prominin1) or CD15 (SSEA-1), these cells
form self-renewing neurospheres in vitro
andgive rise to tumors following transplan-
tation (Bao et al., 2006; Son et al., 2009).
To determine whether S100b-verbB oligo-
dendrogliomas also contain TICs, Persson
et al. (2010) fractionated tumor cells by
flow cytometry and found that CD15+
tumor cells could form neurospheres but
could not initiate tumors following trans-
plantation. In contrast, OPC-like NG2+
cells, which showed limited neurosphere-
forming ability, were enriched in tumori-
genic potential. NG2+ cells from human
oligodendrogliomawerealsohighly tumor-
igenic. Thus, progenitor-like rather than
stem-like cells are responsible for propa-
gation of oligodendrogliomas.
High-grade astrocytomas are ex-
tremely resistant to radiation and chemo-
therapy, and this has been suggested to
be due to intrinsic resistance of their
TICs (Bao et al., 2006). Oligodendroglio-
mas are often more sensitive to therapy,
Figure 1. Cell of Origin and Oncogenic Mutations Collaborate to Determine Glioma Behavior
Activation of growth factor (EGF, PDGF) or Ras-MAP kinase (H-Ras, B-raf, NF-1) signaling pathways in
neural stem cells (NSCs) or progenitors usually results in hyperplasia or low-grade gliomas; mutations
in tumor suppressors (p53, PTEN, Ink4a/Arf) convert these to high-grade tumors. When genetic lesions
are targeted to NSCs or astrocyte progenitors (APCs), the resulting tumors (astrocytomas) retain stem
cell characteristics: multipotency, neurosphere formation, and resistance to therapy. When mutations
are initiated in oligodendrocyte progenitors (OPCs), the resulting tumors (oligodendrogliomas) have
characteristics of OPCs, including restricted differentiation, poor neurosphere formation and sensitivity
to therapy. (Illustration by Jill Gregory.)
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that this might be a property of the glial
progenitors from which they arise. To
test this, they treated progenitors, stem
cells, astrocytomas, and oligodendroglio-
mas with temozolomide, an alkylating
agent used for glioma therapy. Whereas
normal NSCs and astrocytoma cells
were largely resistant to the drug, normal
OPCs and oligodendroglioma cells were
markedly growth-inhibited. These studies
demonstrate that TICs from oligodendro-
glioma, unlike their counterparts from
astrocytoma, are therapy-sensitive.
The present study echoes previous
reports that medulloblastomas can arise
from, and be propagated by, progenitor-
like cells (Read et al., 2009; Yang et al.,
2008). These studies emphasize that the
capacity for tumor initiation and propaga-
tion is not restricted to cells with stem cellcharacteristics. An important implication
of this work is that in searching for novel
approaches to therapy, we must carefully
consider the nature of the tumor we are
trying to target: just as normal progenitors
and stem cells depend on distinct signals
for their growth and survival, tumors
derived from these cells may be driven
by distinct signals and may require
different approaches to therapy. Although
stem cell-specific therapies are certainly
worth developing, they may not be useful
for all types of cancer.
The findings of Persson et al. (2010)
elegantly demonstrate that v-erbB and
p53 mutations can transform OPCs into
oligodendrogliomas. But it is interesting
to consider what would happen if the
same oncogenic events were induced in
multipotent NSCs: would the stem cells
simply differentiate into OPCs and giveCancer Cell 18, Drise to the same type of tumor (as was re-
ported for medulloblastoma [Yang et al.,
2008]) or would targeting these lesions
to stem cells result in astrocytoma, as
has been seen with oncogenic Ras and
Akt or with loss of NF1, p53, and PTEN
(Alcantara Llaguno et al., 2009; Marumoto
et al., 2009). It is tempting to speculate
that the cell of origin dictates the pheno-
type of a tumor (astrocytic or oligoden-
droglial) and that the oncogenicmutations
it contains determine its grade or aggres-
siveness. But given the propensity of
some signals to induce dedifferentiation
(Dai et al., 2001), the truth is likely to be
more complicated. In the end, the proper-
ties of a tumor are likely to depend on the
mutations that drive cell growth and
survival as well as the cellular context in
which these mutations take place.
Knowing where a stranger comes from
can certainly tell you a lot about their char-
acter, but checking if they have a criminal
record may also help: even good families
occasionally have malignant children.
REFERENCES
Alcantara Llaguno, S., Chen, J., Kwon, C.H., Jack-
son, E.L., Li, Y., Burns, D.K., Alvarez-Buylla, A.,
and Parada, L.F. (2009). Cancer Cell 15, 45–56.
Assanah, M., Lochhead, R., Ogden, A., Bruce, J.,
Goldman, J., and Canoll, P. (2006). J. Neurosci.
26, 6781–6790.
Bao, S., Wu, Q., McLendon, R.E., Hao, Y., Shi, Q.,
Hjelmeland, A.B., Dewhirst, M.W., Bigner, D.D.,
and Rich, J.N. (2006). Nature 444, 756–760.
Dai, C., Celestino, J.C., Okada, Y., Louis, D.N.,
Fuller, G.N., and Holland, E.C. (2001). Genes Dev.
15, 1913–1925.
Ivkovic, S., Canoll, P., and Goldman, J.E. (2008).
J. Neurosci. 28, 914–922.
Marumoto, T., Tashiro, A., Friedmann-Morvinski,
D., Scadeng, M., Soda, Y., Gage, F.H., and Verma,
I.M. (2009). Nat. Med. 15, 110–116.
Persson, A.I., Petritsch, C., Swartling, F.J., Itsara,
M., Sim, F.J., Auvergne, R., Goldenberg, D.D.,
Vandenberg, S.R., Nguyen, K.N., Yakovenko, S.,
et al. (2010). Cancer Cell 18, this issue, 669–682.
Read, T.A., Fogarty, M.P., Markant, S.L., McLen-
don, R.E., Wei, Z., Ellison, D.W., Febbo, P.G.,
and Wechsler-Reya, R.J. (2009). Cancer Cell 15,
135–147.
Son, M.J., Woolard, K., Nam, D.H., Lee, J., and
Fine, H.A. (2009). Cell Stem Cell 4, 440–452.
Yang, Z.J., Ellis, T., Markant, S.L., Read, T.A.,
Kessler, J.D., Bourboulas, M., Schu¨ller, U., Mac-
hold, R., Fishell, G., Rowitch, D.H., et al. (2008).
Cancer Cell 14, 135–145.ecember 14, 2010 ª2010 Elsevier Inc. 547
